nach oben

Erschienen in:

23.03.2021 | position paper

2020 update of the Austrian Society of Cardiology (ÖKG) and the Austrian Society of Cardiac Surgery (ÖGHTG) on the position statement of the ÖKG and ÖGHTG for transcatheter aortic valve implantation 2011

verfasst von: Gudrun Lamm, Matthias Hammerer, Uta C. Hoppe, Martin Andreas, Rudolf Berger, Ronald K. Binder, Nikolaos Bonaros, Georg Delle-Karth, Matthias Frick, Michael Grund, Bernhard Metzler, Thomas Neunteufl, Philipp Pichler, Albrecht Schmidt, Wilfried Wisser, Andreas Zierer, Rainald Seitelberger, Michael Grimm, Alexander Geppert, ÖKG and ÖGHTG

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2021

Einloggen, um Zugang zu erhalten

Summary

This position statement is an update to the 2011 consensus statement of the Austrian Society of Cardiology (ÖKG) and the Austrian Society of Cardiac Surgery (ÖGTHG) for transfemoral transcatheter aortic valve implantation.

Due to a number of recently published studies, broadening of indications and recommendations of medical societies and our own national developments, the ÖKG and the ÖGHTG wish to combine the 2017 ESC/EACTS guidelines for the management of valvular heart disease with a national position paper and to focus on certain details for the application in Austria. Thus, this position statement serves as a supplement and further interpretation of the international guidelines.

Vorheriger Artikel Patient engagement in cardiology—nice or necessary?

Nächster Artikel Coronary angiography in patients after cardiac arrest without ST-elevation myocardial infarction

Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–91.PubMedCrossRef

Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609–20.PubMedCrossRef

Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz M, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017;376:1321–31.PubMedCrossRef

Thourani VH, Kodali S, Makkar RR, Herrmann HC, Williams M, Babaliaros V, et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet. 2016;387:2218–25.PubMedCrossRef

Makkar RR, Thourani VH, Mack MJ, Kodali SK, Kapadia S, Webb JG, et al. Five-year outcomes of transcatheter or surgical aortic-valve replacement. N Engl J Med. 2020;382:799–809.PubMedCrossRef

Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695–705.PubMedCrossRef

Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380(18):1706–15.PubMedCrossRef

Dent E, Kowal P, Hoogendijk EO. Frailty measurement in research and clinical practice: a review. Eur J Intern Med. 2016;31:3–10.PubMedCrossRef

Makkar RR, Jilaihawi H, Mack M, Chakravarty T, Cohen DJ, Cheng W, et al. Stratification of outcomes after transcatheter aortic valve replacement according to surgical inoperability for technical versus clinical reasons. J Am Coll Cardiol. 2014;63:901–11.PubMedCrossRef

10.

Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med. 1999;341:142–7.PubMedCrossRef

11.

Beach JM, Mihaljevic T, Svensson LG, Rajeswaran J, Marwick T, Griffin B, et al. Coronary artery disease and outcomes of aortic valve replacement for severe aortic stenosis. J Am Coll Cardiol. 2013;61:837–48.PubMedPubMedCentralCrossRef

12.

Czer LS, Gray RJ, Stewart ME, De Robertis M, Chaux A, Matloff JM. Reduction in sudden late death by concomitant revascularization with aortic valve replacement. J Thorac Cardiovasc Surg. 1988;95:390–401.PubMedCrossRef

13.

Goel SS, Agarwal S, Tuzcu EM, Ellis SG, Svensson LG, Zaman T, et al. Percutaneous coronary intervention in patients with severe aortic stenosis: implications for transcatheter aortic valve replacement. Circulation. 2012;125:1005–13.PubMedCrossRef

14.

Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597–607.PubMedCrossRef

15.

Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2187–98.PubMedCrossRef

16.

Gilard M, Eltchaninoff H, Iung B, Donzeau-Gouge P, Chevreul K, Fajadet J, et al. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med. 2012;366:1705–15.PubMedCrossRef

17.

Nombela-Franco L, Ribeiro HB, Urena M, Allende R, Amat-Santos I, DeLarochelliere R, et al. Significant mitral regurgitation left untreated at the time of aortic valve replacement: a comprehensive review of a frequent entity in the transcatheter aortic valve replacement era. J Am Coll Cardiol. 2014;63:2643–58.PubMedCrossRef

18.

Zahn R, Gerckens U, Linke A, Sievert H, Kahlert P, Hambrecht R, et al. Predictors of one-year mortality after transcatheter aortic valve implantation for severe symptomatic aortic stenosis. Am J Cardiol. 2013;112:272–9.PubMedCrossRef

19.

Chakravarty T, Van Belle E, Jilaihawi H, Noheria A, Testa L, Bedogni F, et al. Meta-analysis of the impact of mitral regurgitation on outcomes after transcatheter aortic valve implantation. Am J Cardiol. 2015;115:942–9.PubMedCrossRef

20.

Diaz R, Hernandez-Vaquero D, Alvarez-Cabo R, Avanzas P, Silva J, Moris C, et al. Long-term outcomes of mechanical versus biological aortic valve prosthesis: systematic review and meta-analysis. J Thorac Cardiovasc Surg. 2019;158:706–714.e18.PubMedCrossRef

21.

Puskas JD, Gerdisch M, Nichols D, Fermin L, Rhenman B, Kapoor D, et al. Anticoagulation and antiplatelet strategies after on‑X mechanical aortic valve replacement. J Am Coll Cardiol. 2018;71:2717–26.PubMedCrossRef

22.

Deeb GM, Reardon MJ, Chetcuti S, Patel HJ, Grossman PM, Yakubov SJ, et al. 3‑year outcomes in high-risk patients who underwent surgical or transcatheter aortic valve replacement. J Am Coll Cardiol. 2016;67:2565–74.PubMedCrossRef

23.

Mack MJ, Leon MB, Smith CR, Miller DC, Moses JW, Tuzcu EM, et al. 5‑year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385:2477–84.PubMedCrossRef

24.

Sondergaard L, Steinbruchel DA, Ihlemann N, Nissen H, Kjeldsen BJ, Petursson P, et al. Two-year outcomes in patients with severe aortic valve stenosis randomized to transcatheter versus surgical aortic valve replacement: the all-comers nordic aortic valve intervention randomized clinical trial. Circ Cardiovasc Interv. 2016;9(6):e3665.PubMedCrossRef

25.

Thyregod HG, Steinbruchel DA, Ihlemann N, Nissen H, Kjeldsen BJ, Petursson P, et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1‑year results from the all-comers NOTION randomized clinical trial. J Am Coll Cardiol. 2015;65:2184–94.PubMedCrossRef

26.

Sondergaard L, Ihlemann N, Capodanno D, Jorgensen TH, Nissen H, Kjeldsen BJ, et al. Durability of transcatheter and surgical bioprosthetic aortic valves in patients at lower surgical risk. J Am Coll Cardiol. 2019;73:546–53.PubMedCrossRef

27.

Kapadia SR, Leon MB, Makkar RR, Tuzcu EM, Svensson LG, Kodali S, et al. 5‑year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385:2485–91.PubMedCrossRef

28.

Siemieniuk RA, Agoritsas T, Manja V, Devji T, Chang Y, Bala MM, et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at low and intermediate risk: systematic review and meta-analysis. BMJ. 2016;354:i5130.PubMedPubMedCentralCrossRef

29.

Vandvik PO, Otto CM, Siemieniuk RA, Bagur R, Guyatt GH, Lytvyn L, et al. Transcatheter or surgical aortic valve replacement for patients with severe, symptomatic, aortic stenosis at low to intermediate surgical risk: a clinical practice guideline. BMJ. 2016;354:i5085.PubMedCrossRef

30.

Carroll JD, Vemulapalli S, Dai D, Matsouaka R, Blackstone E, Edwards F, et al. Procedural experience for transcatheter aortic valve replacement and relation to outcomes: the STS/ACC TVT registry. J Am Coll Cardiol. 2017;70:29–41.PubMedCrossRef

31.

Wassef AWA, Rodes-Cabau J, Liu Y, Webb JG, Barbanti M, Munoz-Garcia AJ, et al. The learning curve and annual procedure volume standards for optimum outcomes of transcatheter aortic valve replacement: findings from an international registry. JACC Cardiovasc Interv. 2018;11:1669–79.PubMedCrossRef

32.

Vemulapalli S, Carroll JD, Mack MJ, Li Z, Dai D, Kosinski AS, et al. Procedural volume and outcomes for transcatheter aortic-valve replacement. N Engl J Med. 2019; https://doi.org/10.1056/NEJMsa1901109.CrossRefPubMed

33.

Bestehorn K, Eggebrecht H, Fleck E, Bestehorn M, Mehta RH, Kuck KH. Volume-outcome relationship with transfemoral transcatheter aortic valve implantation (TAVI): insights from the compulsory German quality assurance registry on aortic valve replacement (AQUA). EuroIntervention. 2017;13:914–20.PubMedCrossRef

34.

Inohara T, Hayashida K, Watanabe Y, Yamamoto M, Takagi K, Yashima F, et al. Streamlining the learning process for TAVI: Insight from a comparative analysis of the OCEAN-TAVI and the massy registries. Catheter Cardiovasc Interv. 2016;87:963–70.PubMedCrossRef

35.

Eggebrecht H, Bestehorn M, Haude M, Schmermund A, Bestehorn K, Voigtlander T, et al. Outcomes of transfemoral transcatheter aortic valve implantation at hospitals with and without on-site cardiac surgery department: insights from the prospective German aortic valve replacement quality assurance registry (AQUA) in 17 919 patients. Eur Heart J. 2016;37:2240–8.PubMedCrossRef

36.

Eggebrecht H, Schmermund A. The current situation and the future of emergent cardiac surgery in TAVI. Interv Cardiol. 2015;10:55–7.PubMedPubMedCentralCrossRef

37.

Pasic M, Unbehaun A, Dreysse S, Buz S, Drews T, Kukucka M, et al. Rupture of the device landing zone during transcatheter aortic valve implantation: a life-threatening but treatable complication. Circ Cardiovasc Interv. 2012;5:424–32.PubMedCrossRef

38.

Hamm CW, Mollmann H, Holzhey D, Beckmann A, Veit C, Figulla HR, et al. The German aortic valve registry (GARY): in-hospital outcome. Eur Heart J. 2014;35:1588–98.PubMedCrossRef

39.

Egger F, Zweiker D, Freynhofer MK, Loffler V, Rohla M, Geppert A, et al. Impact of on-site cardiac surgery on clinical outcomes after transfemoral transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2018;11:2160–7.PubMedCrossRef

40.

Babaliaros V, Devireddy C, Lerakis S, Leonardi R, Iturra SA, Mavromatis K, et al. Comparison of transfemoral transcatheter aortic valve replacement performed in the catheterization laboratory (minimalist approach) versus hybrid operating room (standard approach): outcomes and cost analysis. JACC Cardiovasc Interv. 2014;7:898–904.PubMedCrossRef

41.

Gurevich S, Oestreich B, Kelly RF, Mbai M, Bertog S, Ringsred K, et al. Outcomes of transcatheter aortic valve replacement using a minimalist approach. Cardiovasc Revasc Med. 2018;19:192–5.PubMedCrossRef

42.

Spaziano M, Lefevre T, Romano M, Eltchaninoff H, Leprince P, Motreff P, et al. Transcatheter aortic valve replacement in the catheterization laboratory versus hybrid operating room: insights from the FRANCE TAVI registry. JACC Cardiovasc Interv. 2018;11:2195–203.PubMedCrossRef

43.

Deharo P, Jaussaud N, Grisoli D, Camus O, Resseguier N, Le Breton H, et al. Impact of direct transcatheter aortic valve replacement without balloon aortic valvuloplasty on procedural and clinical outcomes: insights from the FRANCE TAVI registry. JACC Cardiovasc Interv. 2018;11:1956–65.PubMedCrossRef

44.

Toggweiler S, Stortecky S, Holy E, Zuk K, Cuculi F, Nietlispach F, et al. The electrocardiogram after transcatheter aortic valve replacement determines the risk for post-procedural high-degree AV block and the need for telemetry monitoring. JACC Cardiovasc Interv. 2016;9:1269–76.PubMedCrossRef

45.

Brouwer J, et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med. 2020; https://doi.org/10.1056/NEJMoa2017815.CrossRefPubMed

46.

von Scheidt W, et al. Interdisciplinary consensus on indications for transfemoral transcatheter aortic valve implantation (TF-TAVI) : joint consensus document of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte e. V. (ALKK) and cooperating cardiac surgery department. Clin Res Cardiol. 2020;109:1–12.CrossRef

47.

Otto C, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2020; https://doi.org/10.1016/j.jacc.2020.11.018.CrossRefPubMedPubMedCentral

48.

Lamm G. New strategies in the management of valvular heart disease. Wien Klin Wochenschr. 2021. (submitted)

Titel: 2020 update of the Austrian Society of Cardiology (ÖKG) and the Austrian Society of Cardiac Surgery (ÖGHTG) on the position statement of the ÖKG and ÖGHTG for transcatheter aortic valve implantation 2011
verfasst von: Gudrun Lamm
Matthias Hammerer
Uta C. Hoppe
Martin Andreas
Rudolf Berger
Ronald K. Binder
Nikolaos Bonaros
Georg Delle-Karth
Matthias Frick
Michael Grund
Bernhard Metzler
Thomas Neunteufl
Philipp Pichler
Albrecht Schmidt
Wilfried Wisser
Andreas Zierer
Rainald Seitelberger
Michael Grimm
Alexander Geppert
ÖKG and ÖGHTG
Publikationsdatum: 23.03.2021
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 15-16/2021
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-021-01820-3

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 15-16/2021

Beneficial effect of ACE inhibitors on kidney function in polycythemia vera

Utility of procalcitonin in a medical intensive care unit in Croatia

Veranstaltungstipps

Unexpected early migration of a patent foramen ovale occluder

Transcatheter treatment by valve-in-valve and valve-in-ring implantation for prosthetic tricuspid valve dysfunction

Real-world evidence and product development: Opportunities, challenges and risk mitigation